Anuraj Parmanande
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anuraj Parmanande has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- João Vasco Barreira
Universidade Católica Portuguesa, Faculty of Health Sciences and Nursing, Centre for Interdisciplinary Research in Health (CIIS), 1649-023 Lisboa, Portugal
5 shared publications - Mariana Sardinha
Department of Medical Oncology;Centro Clínico Académico de Lisboa, Portugal
3 shared publications - Diana Simão
Medical Oncology, Hospital Santo António dos Capuchos (HSAC), Unidade Local de Saúde São José (ULS São José), Centro Clínico Académico de Lisboa (CCAL), Lisbon, Portugal
2 shared publications R. Luz
2 shared publicationsA. Spencer
1 shared publicationA.F. Palma Dos Reis
1 shared publication
Latest Publications
- Open Access
- 2 September 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-5
Personalized medicine: paradigm shift in ALK positive non-small cell lung cancer: a case report
Background: Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved. In order to guarantee the possibility of longer survival outcomes with a better quality of life we must invest in the determination, in suitable time, of the consensual biomarkers and in the availability of the best treatments to our patients. Case presentation: We present a case of a caucasian male in his fifth decade of life, non-smoker, who highlights the complex journey of ALK-positive patients. This particular case, demonstrates the efficacy and tolerability of the new ALK target therapies, allowing our patients to maintain their routines without compromising the effectiveness of the therapy. Conclusion: Focusing on the reality of ALK positive patients and the impact that this therapy has on the daily lives of our patients, we can contribute to the awareness of this specific pathology.
- 2 September 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-5
Open AccessPersonalized medicine: paradigm shift in ALK positive non-small cell lung cancer: a case report
Background: Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved. In order to guarantee the possibility of longer survival outcomes with a better quality of life we must invest in the determination, in suitable time, of the consensual biomarkers and in the availability of the best treatments to our patients. Case presentation: We present a case of a caucasian male in his fifth decade of life, non-smoker, who highlights the complex journey of ALK-positive patients. This particular case, demonstrates the efficacy and tolerability of the new ALK target therapies, allowing our patients to maintain their routines without compromising the effectiveness of the therapy. Conclusion: Focusing on the reality of ALK positive patients and the impact that this therapy has on the daily lives of our patients, we can contribute to the awareness of this specific pathology.
- Open Access
- 1 January 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 11, e2020230
Bellini duct carcinoma
Autops Case Rep, vol.11, e2020230, 2021
- 1 January 2021
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 11, e2020230
Open AccessBellini duct carcinoma
Autops Case Rep, vol.11, e2020230, 2021
- Open Access
- 1 January 2020
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 10 (3) , e2020179
Full recovery of a stage IV cancer patient facing COVID-19 pandemic
Autops Case Rep, vol.10, n3, e2020179, 2020
- 1 January 2020
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 10 (3) , e2020179
Open AccessFull recovery of a stage IV cancer patient facing COVID-19 pandemic
Autops Case Rep, vol.10, n3, e2020179, 2020
- 15 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3537
Treatment options in metastatic renal cell carcinoma (mRCC): Real-world data from a single institution review
- 15 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3537
Treatment options in metastatic renal cell carcinoma (mRCC): Real-world data from a single institution review
- 15 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3608
Checkpoint inhibitor immune-related adverse events as a prognosis factor in urothelial cancer: A retrospective analysis
- 15 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3608
Checkpoint inhibitor immune-related adverse events as a prognosis factor in urothelial cancer: A retrospective analysis